• Discover real-world clinician and patient experiences with clonoSEQ MRD testing

    Real-world Experience Hub
  • clonoSEQ
    MRD Monitoring

    View the technical summary
  • A patient with CLL tells his MRD story

    Watch Lee's Story
  • A myeloma patient's perspective on MRD

    Watch Tim’s story
  • Adaptive Assist

    Learn More

What is MRD?

Even if you are responding well to treatment or are in remission, a small number of cancer cells can remain in your body, and may cause your disease to return. This is called measurable (or minimal) residual disease, also known as MRD.

Barcodegif Fdd56e3f

With MRD testing, you and your doctor have a personalized way to track—and talk about—your body’s individual response to treatment.


News and Updates

Studies demonstrate value of MRD in novel treatment settings including CAR T cell therapy and in a growing range of patient types, including Non-Hodgkin’s Lymphoma.

View Press Release

December, 2020

Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting

View Press Release

August, 2020

Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia.

View Press Release

This page is intended for a US-based audience.
clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.

Contact Us

Make an inquiry to learn more about our products.